According to Spero Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.94231. At the end of 2022 the company had a P/E ratio of -1.04.
Year | P/E ratio | Change |
---|---|---|
2022 | -1.04 | -81.06% |
2021 | -5.50 | 2.43% |
2020 | -5.37 | 84.35% |
2019 | -2.91 | 24.6% |
2018 | -2.34 | 7.59% |
2017 | -2.17 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
IBM IBM | 21.6 | -463.14% | ๐บ๐ธ USA |
Thomson Reuters
TRI | 30.5 | -612.72% | ๐จ๐ฆ Canada |
Franklin Covey FC | 29.5 | -596.82% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.